Restenosis

Review

Should We Routinely Stent the Femoropopliteal Artery? An Interventionalist`s Perspective

11/01/2015

Nicolas W. Shammas, MD, MS¹ and Subhash Banerjee, MD²

Nicolas W. Shammas, MD, MS1 and Subha...

An overview of the pros and cons of primary stenting of femoropopliteal (FP) arteries vs alternative approaches including provisional stenting following POBA, atherectomy and/or drug-coated balloons.

An overview of the pros and cons...

11/01/2015

Journal of Invasive Cardiology

Original Contribution

Comparison of Rotational Atherectomy, Plain Old Balloon Angioplasty, and Cutting-Balloon Angioplasty Prior to Drug-Eluting Stent Implantation for the Treatment of Heavily Calcified Coronary Lesions

09/02/2015

Wenjie Tian, MD¹; Michael Mahmoudi, MD, PhD²; Thibault Lhermusier, MD¹; Sarkis Kiramijyan, MD¹; Hideaki Ota, MD¹; Fang Chen, PhD¹; Rebecca Torguson, MPH¹; William O. Suddath, MD¹; Lowell F. Satler, MD¹; Augusto D. Pichard, MD¹; Ron Waksman, MD¹

Wenjie Tian, MD1; Michael Mahmoudi, ...

This study compares the clinical outcomes of lesion preparation with rotational atherectomy, plain old balloon angioplasty, or cutting-balloon angioplasty in patients with heavily calcified coronary lesions who were treated with drug-eluting...

This study compares the clinical...

09/02/2015

Journal of Invasive Cardiology

Current Status and Limitations in the Treatment of Femoropopliteal In-Stent Restenosis

08/29/2015

Osamu Iida, MD

Kansai Rosai Hospital Cardiovascular Center, Amagasaki City, Japan

Osamu Iida, MD Kansai Rosai Hospi...

Although endovascular therapy of femoropopliteal lesions with nitinol bare metal stents improves the relatively low primary patency rates achieved with balloon angioplasty, up to 37% of BMS-treated femoropopliteal lesions develop in-stent...

Although endovascular therapy of...

08/29/2015

Vascular Disease Management

Commentary

What Was, What Is, and What Will Be!

07/30/2015

Gerald Dorros, MD, ScD

Dr Dorros warns that in the current health-care climate, cardiologists face the danger of becoming mere technocrats, employed and dictated to by health-care executives, whose main focus is the financial bottom line. Cardiologists must remain...

Dr Dorros warns that in the...

07/30/2015

Journal of Invasive Cardiology

Original Contribution

Clinical Relevance of Poststent Fractional Flow Reserve After Drug-Eluting Stent Implantation

07/30/2015

Joon-Hyung Doh, MD, PhD^1,2; Chang-Wook Nam, MD, PhD³; Bon-Kwon Koo, MD, PhD⁴; Sung Yun Lee, MD, PhD¹; Hyunmin Choi, MD¹; June Namgung, MD, PhD¹; Sung Uk Kwon, MD, PhD¹; Jae-Jin Kwak, MD¹; Hyung-Yoon Kim, MD¹; Won-Ho Choi, MD¹; Won Ro Lee, MD, PhD¹

Joon-Hyung Doh, MD, PhD1,2; Chang-Wo...

The prognostic value of poststent fractional flow reserve (FFR) has not been clearly defined in patients with DES implantation. This study evaluates the association between FFR and clinical outcomes after DES implantation with IVUS...

The prognostic value of...

07/30/2015

Journal of Invasive Cardiology

Interventional Treatment of Superficial Femoral Artery In-Stent Restenosis

07/01/2015

Treatment of in-stent restenosis with standard balloon angioplasty has been associated with poor patency and complications. New therapy options that add lasers and drug-eluting technologies could improve results.

Treatment of in-stent restenosis...

07/01/2015

Vascular Disease Management

Craig Walker, MD, Discusses 12-Month Data From EXCITE ISR

07/01/2015

Dr. Walker, an interventional cardiologist with Cardiovascular Institute of the South and a clinical professor of medicine at Tulane University and LSU medical schools, served as an EXCITE ISR co-principal investigator. Vascular Disease...

Dr. Walker, an interventional...

07/01/2015

Vascular Disease Management

Plaque Composition and Dynamics

Determinants of Neointimal Proliferation and Stent Coverage After Intracoronary Therapy With Drug-Eluting Devices in Stable Coronary Artery Disease: Role of Endothelial Progenitor Cells and Interleukin-1 Family Cytokines

11/26/2014

Sylvia Otto, MD; Kristina Nitsche; Christian Jung, MD; Johannes Gassdorf; Florian Janiak; Bj√∂rn Goebel, MD; Hans R. Figulla, MD; Tudor C. Poerner, MD

Sylvia Otto, MD; Kristina Nitsche; ...

We used OCT to assess the influence of circulating endothelial progenitor cells and levels of Il-1 cytokines on stent coverage and in-stent proliferation. A high EPC count seems to be a favorable individual patient factor, since it was...

We used OCT to assess the...

11/26/2014

Journal of Invasive Cardiology

Original Contribution

Steroids for the Prevention of Restenosis in Bare-Metal Stents: A Systematic Review and Meta-Analysis

02/29/2012

Partha Sardar, MD¹, Saurav Chatterjee, MD², Debabrata Mukherjee, MD, MS³, Kirk N. Garratt, MD¹

¹Lenox Hill Cardiovascular Institute, New York, New York
²Department of Internal Medicine, Maimonides Medical Center, Brooklyn, New York
³the Department of Internal Medicine, Texas Tech Health Sciences Center, El Paso, Texas

Partha Sardar, MD1, Saurav Chatterjee...

Stent restenosis remains a common complication of bare-metal stent (BMS) implantation. Even in the drug-eluting stent (DES) era, there remains a significant proportion of patients who may not be eligible for DES due to inability to comply...

Stent restenosis remains a...

02/29/2012

Journal of Invasive Cardiology

Review

Bare-Stent Technology and Its Utilization in the Treatment of Atherosclerotic Obstructive Disease

04/01/2010

Marco Cura, MD

Following the introduction of percutaneous angioplasty (PTA), arterial stents emerged as a tool for preventing the acute arterial wall recoil and chronic restenosis associated with PTA. The use of stents has grown considerably in the last...

Following the introduction of...

04/01/2010

Vascular Disease Management